Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) shares reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $29.90 and last traded at $28.41, with a volume of 857700 shares trading hands. The stock had previously closed at $27.69.

ADMS has been the subject of several recent analyst reports. BidaskClub cut shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Cowen and Company set a $45.00 price objective on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a report on Wednesday, August 9th. Zacks Investment Research cut shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Finally, JMP Securities reiterated an “outperform” rating and issued a $33.00 price objective (up from $29.00) on shares of Adamas Pharmaceuticals in a report on Friday, August 25th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. Adamas Pharmaceuticals presently has an average rating of “Buy” and an average price target of $42.00.

The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.32 and a current ratio of 8.35.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.01) by ($0.03). During the same quarter last year, the firm posted ($0.66) EPS. The business’s revenue for the quarter was down 99.3% on a year-over-year basis. sell-side analysts expect that Adamas Pharmaceuticals, Inc. will post -3.87 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new stake in Adamas Pharmaceuticals in the 3rd quarter worth approximately $110,000. Quantbot Technologies LP purchased a new stake in Adamas Pharmaceuticals in the 3rd quarter worth approximately $119,000. Tower Research Capital LLC TRC purchased a new stake in Adamas Pharmaceuticals in the 2nd quarter worth approximately $109,000. Sei Investments Co. lifted its position in Adamas Pharmaceuticals by 1,105.0% in the 3rd quarter. Sei Investments Co. now owns 8,760 shares of the specialty pharmaceutical company’s stock worth $185,000 after buying an additional 8,033 shares in the last quarter. Finally, American International Group Inc. lifted its position in Adamas Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock worth $180,000 after buying an additional 682 shares in the last quarter. Institutional investors own 76.24% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Adamas Pharmaceuticals, Inc. (ADMS) Sets New 1-Year High at $29.90” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/adamas-pharmaceuticals-inc-adms-sets-new-1-year-high-at-29-90/1718781.html.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.